China Southern CNI HK Connect Innovative Drug ETF

China Biopharmaceutical's Jointly Promoted Drug Shenghetu Approved for First-Line NSCLC Treatment

China Biopharma's Zongertinib Approved by NMPA as First-Line Treatment for HER2-Mutated NSCLC

Hansoh Pharmaceutical's Self-developed Lung Cancer Drug HS-10504 Approved for Breakthrough Therapy Designation

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

159992

159297

517380

515120

The National Healthcare Security Administration has released a new policy, stating that the pricing mechanism for innovative drugs will no longer solely rely on price reductions, but will instead be dynamically adjusted through a combination of marketization and government regulation. The new mechanism emphasizes multiple factors such as clinical demand, research and development difficulty, and corporate willingness, encouraging companies to set their own prices and promoting reasonable returns for innovative drugs. This policy will change the negotiation strategies of pharmaceutical companies with healthcare insurance, enhance market vitality, and drive industry development

腾讯新闻 - 财经

Yinhua CSI Innovative Drugs Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

GF CSI Innovative Drugs Industry ETF

Good news for innovative drugs! Medical insurance pricing will no longer solely focus on price cuts, but will be dynamically adjusted

688166

159837

560600

159316

520880

159858

159849

516930

159102

513700

588130

On April 15th, China's innovative drug sector collectively rose, with companies like BrightGene experiencing significant growth. The State Council released new policies to optimize the pricing mechanism for innovative drugs, and it is expected that the Class C catalog for medical insurance will be published in 2025, marking the arrival of the incremental payment era for innovative drugs. Huafu Securities predicts that the total transaction volume for innovative drug BD will increase from USD 9.2 billion in 2020 to USD 52.3 billion in 2025, with overseas licensing transaction volume exceeding USD 130 billion by 2025. At the ASCO conference, the number of oral presentations from China reached a historic high, demonstrating the potential and attention surrounding the innovative drug market

BrightGene

E Fund CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Southern CSI Brand Name Drug Industry ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sector uplift, the leap and journey of Chinese innovative drugs

中证医疗

513120

On April 14th, the General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism of Pharmaceuticals," marking the transformation of the pharmaceutical pricing mechanism and promoting high-quality development in the pharmaceutical industry. The new policy formulates differentiated policies for innovative drugs and generic drugs, supports reasonable pricing for innovative drugs, breaks the restrictions of medical insurance payment standards, and encourages enterprise innovation. The generic drug industry will face reshuffling, strengthening centralized procurement regulations, and preventing the impact of low-price bidding on supply. It is expected that small and medium-sized generic drug companies will accelerate elimination, leading to an increase in industry concentration

Hwabao WP CSI Pharmaceuticals ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Innovative Drugs ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Good news! Drug prices are no longer "one-size-fits-all": Innovative drugs can increase prices reasonably, while generic drugs will face survival of the fittest

562600

520500

Zheng Ning has left Bank of China Investment, where the pharmaceutical-themed funds he managed performed excellently, achieving an annual return of 82.67% in 2025. His departure has attracted attention in the fund industry, especially as the equity team faces uncertainty regarding successor candidates. Experts point out that the departure of a core fund manager may impact the company's brand and investor confidence, and investors must confront the uncertainty of the new manager. Zheng Ning's departure is not due to a decline in performance, but rather a highlight of his career

ChinaAMC CSI All Share Health Care Devices ETF

GF Fund CSI Medical Service ETF

Ping An CSI HK Equities Medical and Health Integration ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC CSI Hong Kong Connect Medical Treatment Thematic ETF

Bosera Hang Seng Health Care ETF(QDII)

"Pharmaceutical Ace" Zheng Ning resigns, can the new talent at Bank of China Fund Equity Fund "take up the banner"?

02696

During periods of geopolitical turmoil, the A-share innovative drug sector has performed outstandingly, with an increase in industry prosperity and global pharmaceutical companies increasing their investment in the Chinese market. The total amount of license-out in the Greater China region is expected to reach USD 137.7 billion by 2025, with significant growth in both transaction scale and upfront payments. Recent important cooperation deals, such as those between AstraZeneca and CSPC PHARMA, as well as HENLIUS and Eisai, demonstrate the internationalization trend of Chinese innovative drugs. Despite the unstable external environment, the potential of innovative drugs has not yet been fully reflected in asset prices, and more favorable developments are expected in the future

HENLIUS

CSPC PHARMA

AstraZeneca

Stock Talk | During Geopolitical Turmoil, Why Can A-Share Innovative Drugs Stand Out? The Industrial Logic Has Changed

589720

On March 27th, the Hong Kong Stock Connect Innovative Drug Index rose by 5.07%. CSPC Pharma increased by over 12%, 3SBIO rose by over 9%, and INNOVENT BIO climbed by over 7%. The Hong Kong Stock Connect Innovative Drug ETF, Harvest (520970), had a trading volume of 126 million yuan and a turnover rate of 12.26%. Several Hong Kong Stock Connect innovative drug targets disclosed their 2025 financial reports, with Hengrui Pharma's innovative drug revenue growing by 26% year-on-year. Zhongyou Securities is optimistic about investment opportunities in the sector, while Morgan Stanley believes that the internationalization of China's innovative drugs is accelerating and is currently in a left-side allocation window

Guotai SSE STAR Brand Name Drug ETF

INNOVENT BIO

HENGRUI PHARMA

Harvest CSI Hong Kong Connect Innovative Drugs ETF

Hengrui Pharma

Guotai CSI Hugangshen Innovative Drugs Industry ETF

3SBIO

Wanjia CSI Hong Kong Connect Innovative Drugs ETF

The internationalization of Chinese innovative drugs is accelerating, and the sector is in a left-side allocation window. The Hong Kong Stock Connect Innovative Drug ETF Harvest (520970) is gaining popularity